Iveric Bio patents expiration
1. Izervay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7803931 | IVERIC BIO | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 4 months from now) | |
| US7579456 | IVERIC BIO | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 4 months from now) | |
| US10947544 | IVERIC BIO | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 4 months from now) | |
| US9617546 | IVERIC BIO | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 4 months from now) | |
| US7538211 | IVERIC BIO | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236773 | IVERIC BIO | Aptamer therapeutics useful in the treatment of complement-related disorders |
Nov, 2026
(3 years from now) | |
| US11491176 | IVERIC BIO | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(10 years from now) | |
| US11273171 | IVERIC BIO | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(10 years from now) | |
Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient
Market Authorisation Date: 04 August, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye
Dosage: SOLUTION;INTRAVITREAL
More Information on Dosage
IZERVAY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic